Highbury Group Team
Photo of Ling Wong, General Partner at Highbury Group
Ling Wong
Highbury Group·General Partner
Sweet spot: $10.0M
Range: $500K - $50.0M
Investors in San Francisco (CA), Investors in Seattle (WA)
Investors in Diagnostics (Series A), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Seed), Investors in Diagnostics (Series B), Investors in Pharmaceuticals (Series A), Investors in Diagnostics (Seed), Investors in ClimateTech/CleanTech (Series B), Investors in Diagnostics (Series A), Investors in Health & Hospital Services (Series B), Investors in ClimateTech/CleanTech (Series A), Investors in Digital Health (Series A), Investors in Health & Hospital Services (Series A), Investors in Diagnostics (Series B), Investors in Digital Health (Series B), Investors in Health IT (Series B), Investors in Generative Tech/AI (Series B), Investors in Diagnostics (Seed), Investors in Digital Health (Seed), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Generative Tech/AI (Series A), Investors in BioTech (Series A), Investors in ClimateTech/CleanTech (Seed), Investors in Generative Tech/AI (Seed), Investors in BioTech (Seed), Investors in Consumer Health (Series B), Investors in Diagnostics (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Series A), Investors in Consumer Health (Seed), Investors in Consumer Health (Series A), Investors in Enterprise (Series B), Investors in Pharmaceuticals (Series B), Investors in Health IT (Seed), Investors in Generative Tech/AI (Series B), Investors in Enterprise (Series A), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Seed), Investors in Generative Tech/AI (Series B), Investors in Generative Tech/AI (Series A), Investors in Pharmaceuticals (Series B), Investors in Enterprise (Seed), Investors in ClimateTech/CleanTech (Series B), Investors in Generative Tech/AI (Seed), Investors in Generative Tech/AI (Series A), Investors in Consumer Health (Series B), Investors in Pharmaceuticals (Series A), Investors in Digital Health (Series B), Investors in Pharmaceuticals (Seed), Investors in Generative Tech/AI (Seed), Investors in Consumer Health (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in BioTech (Series B), Investors in ClimateTech/CleanTech (Series B), Investors in ClimateTech/CleanTech (Series A), Investors in Health & Hospital Services (Series B), Investors in Consumer Health (Series A), Investors in Digital Health (Series B), Investors in Health IT (Series B), Investors in Consumer Health (Seed), Investors in BioTech (Series A), Investors in ClimateTech/CleanTech (Seed), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series A), Investors in Digital Health (Series A), Investors in BioTech (Seed), Investors in Consumer Health (Series A), Investors in Health & Hospital Services (Seed), Investors in Health IT (Series A), Investors in Digital Health (Seed), Investors in Consumer Health (Seed), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in Health IT (Seed), Investors in ClimateTech/CleanTech (Series A), Investors in BioTech (Series A), Investors in Enterprise (Series B), Investors in ClimateTech/CleanTech (Seed), Investors in Seattle / Portland (Other Lists), Investors in BioTech (Seed), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Enterprise (Series B), Investors in Enterprise (Series A), Investors in Enterprise (Seed), Investors in Enterprise (Series A), Investors in Enterprise (Seed), Investors in San Francisco Bay Area (Other Lists)